Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07854509) titled 'A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure' on Sept. 28.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Condition: Non-Squamous Non-Small Cell Lung Cancer

Intervention: Drug: SKB264+SKB118

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 15, 2026

Target Sample Size: 110

To know more, visit https://clinicaltrials.gov/study/NCT07854509

Published by HT Digital Conten...